ReviewCurrent oncology reports2015
Targeting Signaling Transduction Pathways in Bladder Cancer.
Review in Current oncology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Serum Tumor Markers for Muscle-Invasive Bladder Cancer in Clinical Practice: A Narrative Review.Cancers · 2025Review
- PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression.Cell & bioscience · 2023Article
- Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.International urology and nephrology · 2022Article
- MINDY1 promotes bladder cancer progression by stabilizing YAP.Cancer cell international · 2021Article
- KIF4A promotes the development of bladder cancer by transcriptionally activating the expression of CDCA3.International journal of molecular medicine · 2021Article
- The Hippo pathway: an emerging role in urologic cancers.American journal of clinical and experimental urology · 2021Review
- Silencing of lncRNA MIR497HG via CRISPR/Cas13d Induces Bladder Cancer Progression Through Promoting the Crosstalk Between Hippo/Yap and TGF-β/Smad Signaling.Frontiers in molecular biosciences · 2020Article
- Behavioral analysis in mice deficient for GAREM2 (Grb2-associated regulator of Erk/MAPK subtype2) that is a subtype of highly expressing in the brain.Molecular brain · 2019Article
- TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.British journal of cancer · 2019Article
- Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer.OncoTargets and therapy · 2019Article
- Whole Genome Messenger RNA Profiling Identifies a Novel Signature to Predict Gastric Cancer Survival.Clinical and translational gastroenterology · 2019Article
- Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer.BMC urology · 2018Article
- Effects of Two-by-Two Combination Therapy with Valproic Acid, Lithium Chloride, and Celecoxib on the Angiogenesis of the Chicken Chorioallantoic Membrane.Iranian journal of medical sciences · 2018Article
- An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.EMBO molecular medicine · 2018Article
- Unmasking molecular profiles of bladder cancer.Investigative and clinical urology · 2018Review
- Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.International journal of medical sciences · 2018Article
- Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.British journal of cancer · 2018Article
- Discovery of Bladder Cancer-related Genes Using Integrative Heterogeneous Network Modeling of Multi-omics Data.Scientific reports · 2017Article
- Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.Cancer cytopathology · 2017Article
- Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic therapy for urothelial carcinoma (UC) of the bladder has largely revolved around cytotoxic chemotherapy regimens. However, several recent clinical trials have explored the roles of targeted therapies which specifically inhibit signal transduction pathways. Simultaneously, a rationale for such therapies has come to the forefront of management of this disease because an overabundance of signaling pathways are genetically deranged as a result of point mutation or copy number alteration (CNA) as identified by several recent next generation sequencing (NGS) studies. Importantly, these derangements are found in all stages of disease, and therefore targeted therapies hold promise as a next step in the evolution of the medical management of both localized and metastatic UCC. We review the rationale for and progress in studying inhibition of signal transduction as a means of treatment of UCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.